Tag Archives: drug discovery

July, 2018

5 July
Enzyvant and Visikol Collaborate to Develop Innovative Digital Pathology Assay to Support RVT-802 Development

BASEL, Switzerland and WHITEHOUSE STATION, N.J., July 5, 2018 /PRNewswire/ — Enzyvant, a biopharmaceutical company focused on developing innovative treatments for patients with rare diseases, today announced that it has formed a partnership with Visikol, a contract research organization focused on digital pathology and drug discovery. Under the terms of …
Share

3 August
Takeda and Molecular Templates Collaborate for Next-Generation Oncology Therapies

OSAKA, Japan & AUSTIN, Texas–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (TSE: 4502) and Molecular Templates, Inc. today announced a collaboration agreement for oncology drug discovery programs. The collaboration will apply Molecular Templates’ engineered toxin bodies (ETB) technology platform to potential therapeutic targets provided by Takeda through a joint scientific committee of …
Share

1 June
Eisai and John Hopkins Extend Drug Discovery Collaboration with New Licensing Agreement

WOODCLIFF LAKE, N.J., May 31, 2017 /PRNewswire/ — Eisai Inc., the U.S. pharmaceutical subsidiary of Tokyo, Japan-based Eisai Co., Ltd., and Johns Hopkins University announced today that they have extended their drug discovery collaboration through an exclusive licensing agreement. The agreement is for a license of compounds identified from collaborative …
Share

30 November
Evotec and Merck KGaA Collaborate for Faster Target Identification Solution

BILLERICA, Mass., Nov. 30, 2016 /PRNewswire/ — Merck, a leading science and technology company, today announced that it has entered into a set of agreements with Evotec AG, whereby Evotec AG will provide screening services for Merck’s collection of genetic reagents such as CRISPR and shRNA libraries. Combining access to …
Share

14 September
Third Rock Launches Relay Therapeutics to Create Breakthrough Medicines Based on Protein Motion

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Third Rock Ventures, LLC today announced the formation of Relay Therapeutics with $57 million in Series A financing, including participation from an affiliate of D. E. Shaw Research, LLC. Relay Therapeutics is building the world’s first dedicated drug discovery platform centered on protein motion, with the aim of …
Share

30 March
Tesaro and MD Anderson Enter Immuno-Oncology Collaboration

WALTHAM, Mass. and HOUSTON, March 29, 2016 (GLOBE NEWSWIRE) — TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, and the Institute for Applied Cancer Science at The University of Texas MD Anderson Cancer Center today announced an exclusive collaboration to discover and develop small molecule product candidates against undisclosed immuno-oncology targets. …
Share